History prepared by some members of the ICH Q9 EWG for example only; not an official policy/guidance July 2006, slide 1 ICH Q9 QUALITY RISK MANAGEMENT.

Slides:



Advertisements
Similar presentations
Project Quality Plans Gillian Sandilands Director of Quality
Advertisements

EPAA Conference 5 November 2007 Georgette LALIS Enterprise and Industry DG European Commission The international dimension of regulatory acceptance.
The New GMP Annex 11 and Chapter 4 Deadline for coming into operation: 30 June 2011.
ICH Q4B Regulatory Acceptance of Analytical Procedures and/or Acceptance Criteria (RAAPAC) Overview and Update Robert H. King, Sr. Office of Pharmaceutical.
Disclaimer The presentation is intended for educational purposes only and does not replace independent professional judgement. Statements of fact and opinions.
Corporate Governance Reform Professor Blanaid Clarke Trinity College Dublin Law Reform Commission Annual Conference 11th December 2012.
Atypical Actives PDA-FDA Conference March 9-10, 2011 David R. Schoneker
Industry's Role in Promoting Best Practices A Collaborative Approach to Food Safety Global Food Safety Policy Forum Washington DC September 16, 2011.
Panel themes of the International Conference “Europe against Counterfeit Medicines” G.N. Gildeeva, Deputy head of the Department of Registration of Medicines.
The United States Experience Implementing the WTO SPS Agreement Hangzhou, China December 2008 Roseanne Freese Senior WTO SPS Affairs Officer United States.
ESSnet Stanprep The CEN Standardisation Process. CEN Overview: A standard (French: Norme, German: Norm) is a technical publication that is used as a rule,
Integrating CMC Review & Inspection Industry Recommendations Joe Anisko April 24, 2003.
What’s New in the FDA’s Pharmaceutical Inspectorate and Risk Based Systems Inspection Rick Perlman Chair Food, Drug, and Cosmetic Division ASQ.
The ICH E5 Question and Answer Document Status and Content Robert T. O’Neill, Ph.D. Director, Office of Biostatistics, CDER, FDA Presented at the 4th Kitasato-Harvard.
FSMA: Where We’ve Been and Where We’re Going Supplemental Notices of Proposed Rulemaking Public Meeting November 13, 2014 Roberta F. Wagner, B.S., M.S.
Frequently Asked Questions (FAQ) prepared by some members of the ICH Q9 EWG for example only; not an official policy/guidance July 2006, slide 1 ICH Q9.
Quality Risk Management ICH Q9 Content
Quality Risk Management ICH Q9 Annex I: Methods & Tools
Presented by: Karen Ginsbury For IFF, Denmark March 2012.
Regulatory requirements and benefits converting to Continued Process Verification.
Welcome ISO9001:2000 Foundation Workshop.
21 CFR Part 11 A Food Industry Perspective FDA Public Meeting June 11, 2004 Sia Economides Center Director Center for Development of Research Policy and.
Executive summary prepared by some members of the ICH Q9 EWG for example only; not an official policy/guidance July 2006, slide 1 ICH Q9 QUALITY RISK MANAGEMENT.
Training Workshop on Pharmaceutical Development with a Focus on Paediatric Medicines / October |1 | Prequalification programme: Priority essential.
Justina A. Molzon, MS Pharm, JD
Overview of ICH Procedures July 2015
Annex I: Methods & Tools prepared by some members of the ICH Q9 EWG for example only; not an official policy/guidance July 2006, slide 1 ICH Q9 QUALITY.
Industry Perspective on Challenges for Product Developers - Drugs Christine Allison, M.S., RAC Associate Regulatory Consultant, Global Regulatory Affairs.
Annex II: Potential Applications prepared by some members of the ICH Q9 EWG for example only; not an official policy/guidance July 2006, slide 1 ICH Q9.
Bioequivalence and Bioavailability Working Group.
ICH V1 An FDA Update Min Chen, M.S., RPh Office of Drug Safety Center for Drug Evaluation and Research FDA January 21, 2003.
CEBS in Brief. The Lamfalussy approach The Lamfalussy approach was first implemented in the securities field following the recommendations of the Committee.
Brussels, 4 June 2010 Introduction I. HOTREC – an umbrella II. HOTREC Fire safety Project.
*The views expressed in this presentation are those of the presenter’s and do not necessarily represent the views of the U.S. Food and Drug Administration.
© 2011 Underwriters Laboratories Inc. All rights reserved. This document may not be reproduced or distributed without authorization. ASSET Safety Management.
FDA’s Perspective on the “Pharmaceutical cGMPs for the 21st Century” Initiative David J. Horowitz, Esq. Director, CDER/FDA, Office of Compliance Advisory.
Important informations
Environmental Management System Definitions
Meeting for EU Generic Manufacturers and EU MA holders for generic medicines, Copenhagen, 26 November 2009 Generics approved by stringent regulatory authorities:
1 Presentation to Legislative Council Panel on Financial Affairs Progress of Implementation of Basel II in Hong Kong Hong Kong Monetary Authority 4 May.
PhRMA Perspective on FDA Final Report FDA Advisory Committee on Pharmaceutical Sciences October 20, 2004 G.P. Migliaccio, Pfizer Inc.
Breakout D Quality Risk Management
Progress in FDA’s Drug Product Quality Initiative Janet Woodcock, M.D. November 13, 2003.
FDA Public Meeting Preparation for the ICH Meetings in Tokyo, Japan, Including Progress on the Common Technical Document and Possibilities for New Topics.
Annex II: Potential Applications prepared by some members of the ICH Q9 EWG for example only; not an official policy/guidance July 2006, slide 1 ICH Q9.
ICH Quality Topics Update
CDER / Office of Compliance ACPS October 5, 2006 Joseph C. Famulare Acting Deputy Director Office of Compliance CDER / FDA.
JMAFF (Chair of Biologicals Quality Monitoring EWG)
VICH General Principles and current update of VICH Outreach Forum activity 1.
-What is VICH, History and Objectives Hervé MARION, DVM VICH Secretariat.
International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use Implementation of ICH Q8, Q9, Q10.
International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use Implementation of ICH Q8, Q9, Q10.
Making Comments Count for High-Impact Regulations and Guidelines in the US Virginia (Ginny) Beakes-Read Executive Director, Global Regulatory Policy and.
INDEX WHAT IS ICH ? HISTORY INITIATION INTRODUCTION TOPICS QUALITY GUDILINES.
How to comment VICH guidelines Shixin XU, PhD, Prof. China IVDC.
Annex II: Potential Applications prepared by some members of the ICH Q9 EWG for example only; not an official policy/guidance July 2006, slide 1 ICH Q9.
POST APPROVAL CHANGE MANAGEMENT PROTOCOLS IN THE EUROPEAN UNION
WHO Technical Briefing Seminar
New legislation impacting IMP
Mutagenic Impurities: Guidances Update w/ CMC Perspectives
Surrey Heath Clinical Commissioning Group
EAST AFRICAN COMMUNITY MEDICINES REGULATORY HARMONIZATION (EAC-MRH) PROJECT PROGRESS NAIROB I - KENYA By: EAC - Secretariat.
ICH-GCP Avinash Kondawar M. Pharm Lead CRA
Michelle Limoli, Pharm.D.
GMP Inspection Process
ICH Q9: Quality Risk Management
ICH Q9: Quality Risk Management
Fundamentals of Electronic Submissions and eCTD
Quality Risk Management ICH Q9 Frequently Asked Questions (FAQ)
Raising the Standards in European Homeopathy
Presentation transcript:

History prepared by some members of the ICH Q9 EWG for example only; not an official policy/guidance July 2006, slide 1 ICH Q9 QUALITY RISK MANAGEMENT Quality Risk Management ICH Q9 History Disclaimer:This presentation includes the authors views on quality risk management theory and practice. The presentation does not represent official guidance or policy of authorities or industry.

History prepared by some members of the ICH Q9 EWG for example only; not an official policy/guidance July 2006, slide 2 ICH Q9 QUALITY RISK MANAGEMENT Purpose of this part is to:  Guide you through the history of the development of the ICH Q9 document  Highlight some of the decisions and rationales for making them

History prepared by some members of the ICH Q9 EWG for example only; not an official policy/guidance July 2006, slide 3 ICH Q9 QUALITY RISK MANAGEMENT The history of Q9 document Osaka November 2003 London March 2004 Washington June 2004 Yokohama November 2004 Draft for consultation March 2005 Chicago November 2005 ICH Q

History prepared by some members of the ICH Q9 EWG for example only; not an official policy/guidance July 2006, slide 4 ICH Q9 QUALITY RISK MANAGEMENT ICH Q9 Milestones November 2003 Osaka March 2004 London June 2004 Washington Nov Yokohama May 2005 Brussels 2006 ongoing Sep Telecon Nov Chicago Feb Telecon March 2005 Steering C. Not legally binding, unless incorporated in local law Consensus of the 6 ICH partners and release for pubic consultation within the 3 Regions Step 2 Scientific discussions within the EWG Step 1 Consolidation of public comments Step 3 Agreement of the 3 ICH regulators and "Signed off" by ICH Steering Committee Step 4 Implementation within the 3 Regions Step 5 ICH Steering Committee agrees to new document Concept paper

History prepared by some members of the ICH Q9 EWG for example only; not an official policy/guidance July 2006, slide 5 ICH Q9 QUALITY RISK MANAGEMENT ICH Concept paper Osaka, November 2003  Technology focus >Increase process capability >Focus on critical control points  Product >Stabilise manufacturing steps (decrease variability) >Guarantee shelf-life  People >Result in a superior performance of the Q-System  Customer >Reduce deviation >Reduce market complaint rate >Reduce technical related adverse events

History prepared by some members of the ICH Q9 EWG for example only; not an official policy/guidance July 2006, slide 6 ICH Q9 QUALITY RISK MANAGEMENT Result of ICH Q9 EWG Meeting London, March 2004  A draft table of contents, flow diagram, definitions were agreed  Assignments to produce first drafts of the full text for each section of the draft table of contents were agreed  Started the dialogue with the ICH Q8 EWG  Regulatory flexibility >The degree to which the final versions of both Q9 and Q8 could refer to 'regulatory relief' was a debate on principles. >Term changed to “regulatory flexibility” or “risk confidence”.

History prepared by some members of the ICH Q9 EWG for example only; not an official policy/guidance July 2006, slide 7 ICH Q9 QUALITY RISK MANAGEMENT ICH Q9 Version 1 “Forget it” expressed what the EWG was thinking in terms of creating text on the agreed content

History prepared by some members of the ICH Q9 EWG for example only; not an official policy/guidance July 2006, slide 8 ICH Q9 QUALITY RISK MANAGEMENT Result of ICH Q9 EWG Meeting Washington, June 2004  Good agreement on overall content >No major disagreements between parties >Training and experience needed  The first official draft (No 2) was issued >All accept that wording is not perfect  Reaching ICH Step 2 in November was still the target >Highly dependent on the extent of comments received on draft

History prepared by some members of the ICH Q9 EWG for example only; not an official policy/guidance July 2006, slide 9 ICH Q9 QUALITY RISK MANAGEMENT Result of ICH Q9 EWG Telecon September 2004  Optional nature of ICH Q9 to be emphasized  All EWG parties want to push ICH Q9 forward >No support for delaying ICH Q9  Appointments for redrafting in six groups >Subgroup decide on details of Chapter 5 / 6 as annex or not >One subgroup to deal with ICH Q8 relationships  Case studies: >Which ones are appropriate to use in ICH Q8, Q9 or Q10? >Everybody should decide, whether the case studies should be included as an annex in the ICH Q9 document or used as training material - Decision to be made in Yokohama

History prepared by some members of the ICH Q9 EWG for example only; not an official policy/guidance July 2006, slide 10 ICH Q9 QUALITY RISK MANAGEMENT Result of ICH Q9 EWG Meeting November 2004  Milestone: Draft 4 issued as “pre-step 2” document  Major concerns were addressed and resolved  Primary principle: link back to the potential harm to the patient  Integration of QRM into existing systems & regulatory processes will take time  For more details: Peter Gough and Stephan Roenninger, ICH Q9 : Quality Risk Management - an update Regulatory Affairs Journal, 16, 2005, 91-93

History prepared by some members of the ICH Q9 EWG for example only; not an official policy/guidance July 2006, slide 11 ICH Q9 QUALITY RISK MANAGEMENT Result of ICH Q9 EWG Telecon February,  All EWG parties agreed to put Q9 forward to step 2  Training slides will be provided >Slides to be discussed after step 4  Next meeting of the EWG: ICH Meeting, November 2005, Chicago

History prepared by some members of the ICH Q9 EWG for example only; not an official policy/guidance July 2006, slide 12 ICH Q9 QUALITY RISK MANAGEMENT ICH Q9 Expert Working Group (EWG) as of ICH Step 2 Expert Working Group (EWG) Mr. David Horowitz Director, Office of Compliance, CDER Dr. H. Gregg Claycamp Director Scientific Support Staff Ms. Diana Kolaitis District field inspector Mr. Jon Edward Clarke FDA HFD (alternate: Q8) Dr. Greg Guyer (Rapporteur) Merck &Co, Vice President, MMD QA Dr. Georgia Keresty Centocor, Inc.,GlobalBiologicsSupply Vice President, Worldwide Quality Ms. Emer Cooke Head of sector Inspections EMEA Dr. Jacques Morenas Inspection and Companies Directorate AFSSAPS, FEMEA, PIC/S Mr. David Cockburn (alternate) Principal Scientific Administrator EMEA Mr. Peter Gough Lilly, GB, Senior Quality Consultant, Corporate QS Dr. Stephan Rönninger F.Hoffmann-LaRoche, CH, Global Quality Manager Mr.Etienne Ouimette Compliance and Enforcement Coordination division, Health prod. & Food Branch Inspectorate Health CDN Ms. Christine Mundkur International Generic Pharmaceutical Alliance Mr. Frederick Razzaghi Consumer Health Product Association Dr. Sabine Kopp QA & Safety Medicines, WHO Dr. Urs Kopp Head of Inspectorate, Swissmedic Dr. Yukio Hiyama Chief, Third Section: Division of Drugs Mr. Ichiro Tsunoi Compliance & Narcotic division Dr. Yoshihiro Matzuda MHLW, Registration Biol. Dr. Mayumi Shikano Review director Office of biologics Dr. Tamiji Nakanishi Reviewer, Office of new drugs I Dr. Yoshihiro Matsuda Reviewer, Office of new drugs I Mr. Takayoshi Matsumura Eisai, Assistant Manager, Corporate QA Department Mr. Tetsuhito Takarada Mochida Pharm.Deputy Director, Quality Control Mr. Hideo Sasaki (alternate) Nippon Shinyaka Co Ltd, Manager Anal.Chem.Sect.

History prepared by some members of the ICH Q9 EWG for example only; not an official policy/guidance July 2006, slide 13 ICH Q9 QUALITY RISK MANAGEMENT Result of ICH Q9 EWG Meeting Chicago November, Points of discussion and changes to the step 2 document  Separate the “How to do?” (annex) from the “What to do?” (text) and move the tools examples to the annex  Modify original diagram in section 4 >Take an alternative proposal showing communication routes  Move “continuous improvement” to Annex II.1 (see ICH Q10)  Reduce complexity by combining and re-wording the individual sections >“formal” and “informal” risk management referenced >“detectability” as an element in several chapters

History prepared by some members of the ICH Q9 EWG for example only; not an official policy/guidance July 2006, slide 14 ICH Q9 QUALITY RISK MANAGEMENT ICH Q9 Expert Working Gro up (EWG) as of ICH Step 4

History prepared by some members of the ICH Q9 EWG for example only; not an official policy/guidance July 2006, slide 15 ICH Q9 QUALITY RISK MANAGEMENT Publication and implementation of ICH Q9 Legal position of ICH Q9  US / FDA: - Guidance for Industry (June 2006) - By law, guidance documents are not enforceable or binding FDA will use the document internally in this spirit, as well  Japan / MHLW: - Product GMP Guideline “Annex”: ICH Guidelines  EU / EMEA: EUDRALEX Volume 4 - Medicinal Products for Human and Veterinary Use : Good Manufacturing Practice - EU-GMP Vol. 4, Annex 20 - Teams established to update chapters of EU-GMP, NfG etc.

History prepared by some members of the ICH Q9 EWG for example only; not an official policy/guidance July 2006, slide 16 ICH Q9 QUALITY RISK MANAGEMENT European legal position of ICH Q9 Publication of the document in EU for comments:  “It should be borne in mind that this guideline does not introduce new requirements or expectations but should be considered a resource document that can be used together with existing quality-related guidelines when a risk-based approach is appropriate.”  “Therefore, as well as complementing GMP guidelines, the document should be seen as also complementing and supporting existing and future guidelines published by CHMP and CVMP concerning the quality of medicinal products.” EU-Publication of Step 2 document

History prepared by some members of the ICH Q9 EWG for example only; not an official policy/guidance July 2006, slide 17 ICH Q9 QUALITY RISK MANAGEMENT AuthorsReviewers  S. Rönninger, Roche (Chair)  G. Claycamp, FDA  P. Gough, former Lilly  M. Holmes, GSK  T. Matsumura, Eisai Co.  H. Sasaki, Nippon Shinyaku  T. Takarada, Mochida Pharm.  E. Cooke, EMEA  Y. Hiyama, MHLW  D. Horowitz, FDA  G. Keresty, Centocor  U. Kopp, Swissmedic  J. Morénas, AFSSAPS  C. Mundkur, Barr Laboratories  M.-P. Müller, Swissmedic  F. Razzaghi, CHPA Supported by EFPIA and JPMA ICH Q9 topic groups ICH Q9 Briefing Pack July 2006

History prepared by some members of the ICH Q9 EWG for example only; not an official policy/guidance July 2006, slide 18 ICH Q9 QUALITY RISK MANAGEMENT ICH Q9 Briefing Pack Current direct link: ICH EWG members published a set of slides with more details on possible implementations >ICH homepage: -> -> scroll down to ICH Q9www.ich.org  On the ICH Q9 Document >Background >History >Content >Tools >Applications  Additional features >Senior Management Training >Frequently Asked Questions (Q&A)

History prepared by some members of the ICH Q9 EWG for example only; not an official policy/guidance July 2006, slide 19 ICH Q9 QUALITY RISK MANAGEMENT Optional but can benefit from its use!